Cochrane for Clinicians
Putting Evidence into Practice
Magnesium Sulfate and Other Anticonvulsants for Women with Preeclampsia
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2011 Jun 1;83(11):1269-1270.
A 24-year-old primiparous woman presents at term in active labor. She has a headache, a blood pressure reading of 150/100 mm Hg, and an elevated protein/creatinine ratio. Further laboratory studies show normal complete blood count and liver function tests. She is diagnosed with preeclampsia.
Should magnesium sulfate or a different anticonvulsant be given to prevent eclamptic seizures during labor?
Magnesium sulfate should be considered first-line treatment to prevent eclamptic seizures during labor. (Strength of Recommendation = A, based on consistent, good-quality patient-oriented evidence)
Preeclampsia is common, occurring in 3 to 8 percent of U.S. pregnancies.1 Eclampsia, however, is a less common complication characterized by seizures; it occurs as often as once in 100 pregnancies in some low-income countries, but affects only one in 2,000 pregnancies in the United Kingdom.1 Severe preeclampsia is typically defined as blood pressure greater than 160/100 mm Hg and/or protein level greater than 5 g on a 24-hour urine collection. These patients may have a platelet count less than 100 × 103 per μL (100 × 109 per L); increased transaminase or lactate dehydrogenase levels; persistent headache; right upper quadrant pain; visual changes; less than 500 mL of urine output over 24 hours; or a fetus with intrauterine growth restriction.1
Although severe preeclampsia can adversely affect multiple maternal systems, predicting who will have a seizure is difficult. Because the treatment of choice for eclamptic seizures is magnesium sulfate, it seems reasonable to also consider using it for prevention.2 However, a number of other medications are available for seizure prevention, including phenytoin (Dilantin) and nimodipine (Nimotop).
This Cochrane review supports the use of magnesium sulfate over other medications for the prevention of eclamptic seizures.2 Since the last review update in 2003, the authors added two studies: one from 1998 in Mexico involving 36 women, and one from 2008 in India involving 50 women with preeclampsia. The results of both studies were consistent with the previous review's conclusions. Further, they contributed to the heterogeneity of the review, which featured several large and small studies from a variety of different-sized and geographically diverse hospitals. Therefore, these results have broad implications.
Women with mild preeclampsia seize less often than those with severe preeclampsia, and a 2004 review of trials suggested no benefit to prophylactic use of magnesium sulfate in those with mild preeclampsia.3 However, this Cochrane review found a statistically significant reduction in eclampsia for women with severe preeclampsia (number needed to treat = 50; 95% confidence interval, 34 to 100), as well as for women with “not severe” preeclampsia (number needed to treat = 100; 95% confidence interval, 100 to 500).2
Compared with no treatment or another form of seizure prevention, magnesium sulfate increases the risk of cesarean delivery and adverse effects ranging from flushing and nausea to respiratory and cardiac suppression and death. However, there was no increased risk of negative long-term outcomes to the child at 18 months of age. Although cost-effectiveness is higher if treatment is limited to women with severe preeclampsia, magnesium sulfate remains a low-cost, widely available therapy.4 The American College of Obstetricians and Gynecologists recommends the use of magnesium sulfate as first-line therapy to prevent seizures in women with preeclampsia.1
Background: Eclampsia, the occurrence of a seizure in association with preeclampsia, is rare but potentially life-threatening. Magnesium sulfate is the drug of choice for treating eclampsia. This review assesses its use for preventing eclampsia.
Objectives: To assess the effects of magnesium sulfate and other anticonvulsants for prevention of eclampsia.
Search Strategy: The authors searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 4, 2010), and the Cochrane Central Register of Controlled Trials Register (The Cochrane Library 2010, Issue 3).
Selection Criteria: Randomized trials comparing anticonvulsants with placebo or no anticonvulsant, or comparisons of different drugs, for preeclampsia.
Data Collection and Analysis: Two authors assessed trial quality and extracted data independently.
Main Results: The authors included 15 trials. Six (n = 11,444 women) compared magnesium sulfate with placebo or no anticonvulsant: magnesium sulfate reduced the risk of eclampsia by more than one-half (risk ratio [RR] = 0.41; 95% confidence interval [CI], 0.29 to 0.58; number needed to treat for an additional beneficial outcome [NNTB] = 100; 95% CI, 50 to 100), with a nonsignificant reduction in maternal death (RR = 0.54; 95% CI, 0.26 to 1.10) but no clear difference in serious maternal morbidity (RR = 1.08; 95% CI, 0.89 to 1.32). It reduced the risk of placental abruption (RR = 0.64; 95% CI, 0.50 to 0.83; NNTB = 100; 95% CI, 50 to 1,000) and increased cesarean delivery (RR = 1.05; 95% CI, 1.01 to 1.10). There was no clear difference in stillbirth or neonatal death (RR = 1.04; 95% CI, 0.93 to 1.15).
Adverse effects, primarily flushing, were more common with magnesium sulfate (24 versus 5 percent; RR = 5.26; 95% CI, 4.59 to 6.03; number need to treat for an additional harmful outcome = 6; 95% CI, 5 to 6). Follow-up was reported by one trial comparing magnesium sulfate with placebo: for 3,375 women there was no clear difference in death (RR = 1.79; 95% CI, 0.71 to 4.53) or morbidity potentially related to preeclampsia (RR = 0.84; 95% CI, 0.55 to 1.26; median follow-up of 26 months); for 3,283 children exposed in utero, there was no clear difference in death (RR = 1.02; 95% CI, 0.57 to 1.84) or neurosensory disability (RR = 0.77; 95% CI, 0.38 to 1.58) at 18 months of age. Magnesium sulfate reduced eclampsia compared with phenytoin (three trials, 2,291 women; RR = 0.08; 95% CI, 0.01 to 0.60) and nimodipine (one trial, 1,650 women; RR = 0.33; 95% CI, 0.14 to 0.77).
Authors' Conclusions: Magnesium sulfate reduces the risk of eclampsia by more than one-half, and probably reduces maternal death. There is no clear effect on outcome after hospital discharge. One-fourth of women report adverse effects with magnesium sulfate.
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org).
REFERENCESshow all references
1. ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159–167....
2. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with preeclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025.
3. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190(6):1520–1526.
4. Simon J, Gray A, Duley L; Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG. 2006;113(2):144–151.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Dr. Fogleman presents a clinical scenario and question based on the Cochrane Abstract, followed by an evidence-based answer and a critique of the review. The practice recommendations in this activity are available at http://www.cochrane.org/reviews/en/ab000025.html.
The series coordinator for AFP is Kenny Lin, MD, Department of Family Medicine, Georgetown University School of Medicine, Washington, DC.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Sep 15, 2016
Access the latest issue of American Family Physician